Exact Sciences Corporation
Exact Sciences Corporation (EXAS) Stock Competitors & Peer Comparison
See (EXAS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EXAS | $45.66 | -3.81% | 8.6B | -8.38 | -$5.45 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.57% |
| TMO | $490.75 | -1.85% | 185.2B | 28.36 | $17.30 | +0.33% |
| DHR | $207.73 | -1.92% | 148.8B | 44.20 | $4.70 | +0.57% |
| IDXX | $641.35 | -0.65% | 51.3B | 53.40 | $12.01 | N/A |
| A | $119.15 | -2.04% | 33.8B | 29.33 | $4.06 | +0.83% |
| IQV | $188.02 | -1.64% | 32B | 27.25 | $6.90 | N/A |
| MTD | $1,289.78 | -2.40% | 26.6B | 32.76 | $39.38 | N/A |
| NTRA | $162.47 | -1.89% | 22.3B | -85.51 | -$1.90 | N/A |
| DGX | $178.66 | -0.87% | 20B | 21.42 | $8.34 | +1.73% |
Stock Comparison
EXAS vs DHR-PB Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, EXAS is priced at $45.66, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, EXAS's ROE is -0.38%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, EXAS is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check DHR-PB's competition here
EXAS vs TMO Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, TMO has a market cap of 185.2B. Regarding current trading prices, EXAS is priced at $45.66, while TMO trades at $490.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas TMO's P/E ratio is 28.36. In terms of profitability, EXAS's ROE is -0.38%, compared to TMO's ROE of +0.13%. Regarding short-term risk, EXAS is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check TMO's competition here
EXAS vs DHR Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, DHR has a market cap of 148.8B. Regarding current trading prices, EXAS is priced at $45.66, while DHR trades at $207.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas DHR's P/E ratio is 44.20. In terms of profitability, EXAS's ROE is -0.38%, compared to DHR's ROE of +0.07%. Regarding short-term risk, EXAS is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check DHR's competition here
EXAS vs IDXX Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, IDXX has a market cap of 51.3B. Regarding current trading prices, EXAS is priced at $45.66, while IDXX trades at $641.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas IDXX's P/E ratio is 53.40. In terms of profitability, EXAS's ROE is -0.38%, compared to IDXX's ROE of +0.64%. Regarding short-term risk, EXAS is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check IDXX's competition here
EXAS vs A Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, A has a market cap of 33.8B. Regarding current trading prices, EXAS is priced at $45.66, while A trades at $119.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas A's P/E ratio is 29.33. In terms of profitability, EXAS's ROE is -0.38%, compared to A's ROE of +0.19%. Regarding short-term risk, EXAS is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check A's competition here
EXAS vs IQV Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, IQV has a market cap of 32B. Regarding current trading prices, EXAS is priced at $45.66, while IQV trades at $188.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas IQV's P/E ratio is 27.25. In terms of profitability, EXAS's ROE is -0.38%, compared to IQV's ROE of +0.20%. Regarding short-term risk, EXAS is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check IQV's competition here
EXAS vs MTD Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, MTD has a market cap of 26.6B. Regarding current trading prices, EXAS is priced at $45.66, while MTD trades at $1,289.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas MTD's P/E ratio is 32.76. In terms of profitability, EXAS's ROE is -0.38%, compared to MTD's ROE of -4.60%. Regarding short-term risk, EXAS is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check MTD's competition here
EXAS vs NTRA Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, NTRA has a market cap of 22.3B. Regarding current trading prices, EXAS is priced at $45.66, while NTRA trades at $162.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas NTRA's P/E ratio is -85.51. In terms of profitability, EXAS's ROE is -0.38%, compared to NTRA's ROE of -0.22%. Regarding short-term risk, EXAS is more volatile compared to NTRA. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check NTRA's competition here
EXAS vs DGX Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, DGX has a market cap of 20B. Regarding current trading prices, EXAS is priced at $45.66, while DGX trades at $178.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas DGX's P/E ratio is 21.42. In terms of profitability, EXAS's ROE is -0.38%, compared to DGX's ROE of +0.14%. Regarding short-term risk, EXAS is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check DGX's competition here
EXAS vs WAT Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, WAT has a market cap of 17.8B. Regarding current trading prices, EXAS is priced at $45.66, while WAT trades at $298.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas WAT's P/E ratio is 26.96. In terms of profitability, EXAS's ROE is -0.38%, compared to WAT's ROE of +0.35%. Regarding short-term risk, EXAS is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check WAT's competition here
EXAS vs ILMN Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, ILMN has a market cap of 15.3B. Regarding current trading prices, EXAS is priced at $45.66, while ILMN trades at $99.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas ILMN's P/E ratio is 12.62. In terms of profitability, EXAS's ROE is -0.38%, compared to ILMN's ROE of +0.53%. Regarding short-term risk, EXAS is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check ILMN's competition here
EXAS vs PKI Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, EXAS is priced at $45.66, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas PKI's P/E ratio is 41.45. In terms of profitability, EXAS's ROE is -0.38%, compared to PKI's ROE of +0.04%. Regarding short-term risk, EXAS is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check PKI's competition here
EXAS vs ICLR Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, ICLR has a market cap of 13.4B. Regarding current trading prices, EXAS is priced at $45.66, while ICLR trades at $171.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas ICLR's P/E ratio is 17.69. In terms of profitability, EXAS's ROE is -0.38%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, EXAS is more volatile compared to ICLR. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check ICLR's competition here
EXAS vs MEDP Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, MEDP has a market cap of 13.1B. Regarding current trading prices, EXAS is priced at $45.66, while MEDP trades at $466.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas MEDP's P/E ratio is 34.71. In terms of profitability, EXAS's ROE is -0.38%, compared to MEDP's ROE of +0.68%. Regarding short-term risk, EXAS is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check MEDP's competition here
EXAS vs TEM Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, TEM has a market cap of 12.8B. Regarding current trading prices, EXAS is priced at $45.66, while TEM trades at $75.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas TEM's P/E ratio is 35.30. In terms of profitability, EXAS's ROE is -0.38%, compared to TEM's ROE of -1.07%. Regarding short-term risk, EXAS is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check TEM's competition here
EXAS vs RVTY Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, RVTY has a market cap of 10.7B. Regarding current trading prices, EXAS is priced at $45.66, while RVTY trades at $92.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas RVTY's P/E ratio is 40.05. In terms of profitability, EXAS's ROE is -0.38%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, EXAS is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check RVTY's competition here
EXAS vs QGEN Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, QGEN has a market cap of 10.6B. Regarding current trading prices, EXAS is priced at $45.66, while QGEN trades at $48.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas QGEN's P/E ratio is 28.59. In terms of profitability, EXAS's ROE is -0.38%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, EXAS is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check QGEN's competition here
EXAS vs CRL Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, CRL has a market cap of 8.1B. Regarding current trading prices, EXAS is priced at $45.66, while CRL trades at $164.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas CRL's P/E ratio is -127.17. In terms of profitability, EXAS's ROE is -0.38%, compared to CRL's ROE of -0.02%. Regarding short-term risk, EXAS is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check CRL's competition here
EXAS vs GH Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, GH has a market cap of 7.7B. Regarding current trading prices, EXAS is priced at $45.66, while GH trades at $61.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas GH's P/E ratio is -18.47. In terms of profitability, EXAS's ROE is -0.38%, compared to GH's ROE of +2.19%. Regarding short-term risk, EXAS is more volatile compared to GH. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check GH's competition here
EXAS vs RDNT Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, RDNT has a market cap of 5.4B. Regarding current trading prices, EXAS is priced at $45.66, while RDNT trades at $69.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas RDNT's P/E ratio is -347.95. In terms of profitability, EXAS's ROE is -0.38%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, EXAS is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check RDNT's competition here
EXAS vs SHC Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, SHC has a market cap of 4.7B. Regarding current trading prices, EXAS is priced at $45.66, while SHC trades at $16.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas SHC's P/E ratio is 182.11. In terms of profitability, EXAS's ROE is -0.38%, compared to SHC's ROE of +0.05%. Regarding short-term risk, EXAS is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check SHC's competition here
EXAS vs SYNH Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, EXAS is priced at $45.66, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas SYNH's P/E ratio is 61.40. In terms of profitability, EXAS's ROE is -0.38%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, EXAS is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check SYNH's competition here
EXAS vs OLK Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, EXAS is priced at $45.66, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas OLK's P/E ratio is -96.59. In terms of profitability, EXAS's ROE is -0.38%, compared to OLK's ROE of -0.07%. Regarding short-term risk, EXAS is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check OLK's competition here
EXAS vs TWST Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, TWST has a market cap of 1.7B. Regarding current trading prices, EXAS is priced at $45.66, while TWST trades at $27.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas TWST's P/E ratio is -19.02. In terms of profitability, EXAS's ROE is -0.38%, compared to TWST's ROE of -0.18%. Regarding short-term risk, EXAS is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check TWST's competition here
EXAS vs VIVO Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, EXAS is priced at $45.66, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas VIVO's P/E ratio is 21.09. In terms of profitability, EXAS's ROE is -0.38%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, EXAS is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check VIVO's competition here
EXAS vs NEOG Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, NEOG has a market cap of 1.2B. Regarding current trading prices, EXAS is priced at $45.66, while NEOG trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas NEOG's P/E ratio is -1.11. In terms of profitability, EXAS's ROE is -0.38%, compared to NEOG's ROE of -0.41%. Regarding short-term risk, EXAS is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NEOG's competition here
EXAS vs GRAL Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, GRAL has a market cap of 1.2B. Regarding current trading prices, EXAS is priced at $45.66, while GRAL trades at $32.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas GRAL's P/E ratio is -2.81. In terms of profitability, EXAS's ROE is -0.38%, compared to GRAL's ROE of -0.18%. Regarding short-term risk, EXAS is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check GRAL's competition here
EXAS vs OPK Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, EXAS is priced at $45.66, while OPK trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas OPK's P/E ratio is -5.35. In terms of profitability, EXAS's ROE is -0.38%, compared to OPK's ROE of -0.13%. Regarding short-term risk, EXAS is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check OPK's competition here
EXAS vs CDNA Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, CDNA has a market cap of 678.6M. Regarding current trading prices, EXAS is priced at $45.66, while CDNA trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas CDNA's P/E ratio is 12.14. In terms of profitability, EXAS's ROE is -0.38%, compared to CDNA's ROE of +0.15%. Regarding short-term risk, EXAS is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check CDNA's competition here
EXAS vs FLGT Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, FLGT has a market cap of 659M. Regarding current trading prices, EXAS is priced at $45.66, while FLGT trades at $21.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas FLGT's P/E ratio is -12.97. In terms of profitability, EXAS's ROE is -0.38%, compared to FLGT's ROE of -0.05%. Regarding short-term risk, EXAS is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check FLGT's competition here
EXAS vs CSTL Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, CSTL has a market cap of 596.7M. Regarding current trading prices, EXAS is priced at $45.66, while CSTL trades at $20.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas CSTL's P/E ratio is -60.50. In terms of profitability, EXAS's ROE is -0.38%, compared to CSTL's ROE of -0.02%. Regarding short-term risk, EXAS is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check CSTL's competition here
EXAS vs GRALV Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, EXAS is priced at $45.66, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas GRALV's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.38%, compared to GRALV's ROE of N/A. Regarding short-term risk, EXAS is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check GRALV's competition here
EXAS vs MYGN Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, MYGN has a market cap of 548M. Regarding current trading prices, EXAS is priced at $45.66, while MYGN trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas MYGN's P/E ratio is -1.37. In terms of profitability, EXAS's ROE is -0.38%, compared to MYGN's ROE of -0.63%. Regarding short-term risk, EXAS is more volatile compared to MYGN. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check MYGN's competition here
EXAS vs LAB Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, LAB has a market cap of 473.7M. Regarding current trading prices, EXAS is priced at $45.66, while LAB trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas LAB's P/E ratio is -3.35. In terms of profitability, EXAS's ROE is -0.38%, compared to LAB's ROE of -0.26%. Regarding short-term risk, EXAS is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check LAB's competition here
EXAS vs PSNL Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, PSNL has a market cap of 416.8M. Regarding current trading prices, EXAS is priced at $45.66, while PSNL trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas PSNL's P/E ratio is -3.67. In terms of profitability, EXAS's ROE is -0.38%, compared to PSNL's ROE of -0.48%. Regarding short-term risk, EXAS is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check PSNL's competition here
EXAS vs CO Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, EXAS is priced at $45.66, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas CO's P/E ratio is 5.06. In terms of profitability, EXAS's ROE is -0.38%, compared to CO's ROE of +0.11%. Regarding short-term risk, EXAS is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check CO's competition here
EXAS vs FLDM Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, EXAS is priced at $45.66, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas FLDM's P/E ratio is -4.74. In terms of profitability, EXAS's ROE is -0.38%, compared to FLDM's ROE of -0.51%. Regarding short-term risk, EXAS is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check FLDM's competition here
EXAS vs ATLN Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, ATLN has a market cap of 284.2M. Regarding current trading prices, EXAS is priced at $45.66, while ATLN trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas ATLN's P/E ratio is -2.46. In terms of profitability, EXAS's ROE is -0.38%, compared to ATLN's ROE of +13.74%. Regarding short-term risk, EXAS is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ATLN's competition here
EXAS vs XGN Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, XGN has a market cap of 216.7M. Regarding current trading prices, EXAS is priced at $45.66, while XGN trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas XGN's P/E ratio is -11.07. In terms of profitability, EXAS's ROE is -0.38%, compared to XGN's ROE of -1.36%. Regarding short-term risk, EXAS is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check XGN's competition here
EXAS vs STIM Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, STIM has a market cap of 211.6M. Regarding current trading prices, EXAS is priced at $45.66, while STIM trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas STIM's P/E ratio is -2.78. In terms of profitability, EXAS's ROE is -0.38%, compared to STIM's ROE of -1.94%. Regarding short-term risk, EXAS is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check STIM's competition here
EXAS vs ACRS Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, ACRS has a market cap of 195M. Regarding current trading prices, EXAS is priced at $45.66, while ACRS trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas ACRS's P/E ratio is -1.15. In terms of profitability, EXAS's ROE is -0.38%, compared to ACRS's ROE of -0.96%. Regarding short-term risk, EXAS is more volatile compared to ACRS. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check ACRS's competition here
EXAS vs MDXH Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, MDXH has a market cap of 175.2M. Regarding current trading prices, EXAS is priced at $45.66, while MDXH trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas MDXH's P/E ratio is -4.66. In terms of profitability, EXAS's ROE is -0.38%, compared to MDXH's ROE of -4.78%. Regarding short-term risk, EXAS is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check MDXH's competition here
EXAS vs NEO Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, NEO has a market cap of 164.3M. Regarding current trading prices, EXAS is priced at $45.66, while NEO trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas NEO's P/E ratio is -7.87. In terms of profitability, EXAS's ROE is -0.38%, compared to NEO's ROE of -0.12%. Regarding short-term risk, EXAS is more volatile compared to NEO. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check NEO's competition here
EXAS vs GTH Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, EXAS is priced at $45.66, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas GTH's P/E ratio is -1.11. In terms of profitability, EXAS's ROE is -0.38%, compared to GTH's ROE of -1.01%. Regarding short-term risk, EXAS is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check GTH's competition here
EXAS vs GENE Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, EXAS is priced at $45.66, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas GENE's P/E ratio is -38.25. In terms of profitability, EXAS's ROE is -0.38%, compared to GENE's ROE of -3.06%. Regarding short-term risk, EXAS is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check GENE's competition here
EXAS vs SERA Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, SERA has a market cap of 97.9M. Regarding current trading prices, EXAS is priced at $45.66, while SERA trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas SERA's P/E ratio is -3.11. In terms of profitability, EXAS's ROE is -0.38%, compared to SERA's ROE of -0.46%. Regarding short-term risk, EXAS is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check SERA's competition here
EXAS vs PRE Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, PRE has a market cap of 95.9M. Regarding current trading prices, EXAS is priced at $45.66, while PRE trades at $7.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas PRE's P/E ratio is -1.93. In terms of profitability, EXAS's ROE is -0.38%, compared to PRE's ROE of -0.28%. Regarding short-term risk, EXAS is more volatile compared to PRE. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check PRE's competition here
EXAS vs PRENW Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, PRENW has a market cap of 81.4M. Regarding current trading prices, EXAS is priced at $45.66, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas PRENW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.38%, compared to PRENW's ROE of -0.28%. Regarding short-term risk, EXAS is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check PRENW's competition here
EXAS vs VNRX Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, VNRX has a market cap of 73.7M. Regarding current trading prices, EXAS is priced at $45.66, while VNRX trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas VNRX's P/E ratio is -2.86. In terms of profitability, EXAS's ROE is -0.38%, compared to VNRX's ROE of +0.88%. Regarding short-term risk, EXAS is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check VNRX's competition here
EXAS vs BDSX Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, BDSX has a market cap of 71.8M. Regarding current trading prices, EXAS is priced at $45.66, while BDSX trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas BDSX's P/E ratio is -1.88. In terms of profitability, EXAS's ROE is -0.38%, compared to BDSX's ROE of -2.70%. Regarding short-term risk, EXAS is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BDSX's competition here
EXAS vs NOTV Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, NOTV has a market cap of 59.8M. Regarding current trading prices, EXAS is priced at $45.66, while NOTV trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas NOTV's P/E ratio is -0.66. In terms of profitability, EXAS's ROE is -0.38%, compared to NOTV's ROE of -0.49%. Regarding short-term risk, EXAS is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NOTV's competition here
EXAS vs STRRP Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, STRRP has a market cap of 30.5M. Regarding current trading prices, EXAS is priced at $45.66, while STRRP trades at $9.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas STRRP's P/E ratio is -4.74. In terms of profitability, EXAS's ROE is -0.38%, compared to STRRP's ROE of -0.04%. Regarding short-term risk, EXAS is less volatile compared to STRRP. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check STRRP's competition here
EXAS vs AKU Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, EXAS is priced at $45.66, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas AKU's P/E ratio is -0.13. In terms of profitability, EXAS's ROE is -0.38%, compared to AKU's ROE of -5.32%. Regarding short-term risk, EXAS is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check AKU's competition here
EXAS vs DRIO Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, DRIO has a market cap of 25M. Regarding current trading prices, EXAS is priced at $45.66, while DRIO trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas DRIO's P/E ratio is -0.82. In terms of profitability, EXAS's ROE is -0.38%, compared to DRIO's ROE of -0.58%. Regarding short-term risk, EXAS is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check DRIO's competition here
EXAS vs PRPO Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, PRPO has a market cap of 21.4M. Regarding current trading prices, EXAS is priced at $45.66, while PRPO trades at $14.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas PRPO's P/E ratio is -12.02. In terms of profitability, EXAS's ROE is -0.38%, compared to PRPO's ROE of -0.15%. Regarding short-term risk, EXAS is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check PRPO's competition here
EXAS vs CEMI Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, EXAS is priced at $45.66, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas CEMI's P/E ratio is -0.63. In terms of profitability, EXAS's ROE is -0.38%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, EXAS is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check CEMI's competition here
EXAS vs ENZ Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, EXAS is priced at $45.66, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas ENZ's P/E ratio is -2.24. In terms of profitability, EXAS's ROE is -0.38%, compared to ENZ's ROE of -0.44%. Regarding short-term risk, EXAS is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ENZ's competition here
EXAS vs TRIB Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, TRIB has a market cap of 16M. Regarding current trading prices, EXAS is priced at $45.66, while TRIB trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas TRIB's P/E ratio is -0.86. In terms of profitability, EXAS's ROE is -0.38%, compared to TRIB's ROE of +1.12%. Regarding short-term risk, EXAS is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check TRIB's competition here
EXAS vs PMD Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, EXAS is priced at $45.66, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas PMD's P/E ratio is -5.24. In terms of profitability, EXAS's ROE is -0.38%, compared to PMD's ROE of -0.33%. Regarding short-term risk, EXAS is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check PMD's competition here
EXAS vs BNGO Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, BNGO has a market cap of 13.8M. Regarding current trading prices, EXAS is priced at $45.66, while BNGO trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas BNGO's P/E ratio is -0.09. In terms of profitability, EXAS's ROE is -0.38%, compared to BNGO's ROE of -1.67%. Regarding short-term risk, EXAS is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BNGO's competition here
EXAS vs ME Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, EXAS is priced at $45.66, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas ME's P/E ratio is -0.03. In terms of profitability, EXAS's ROE is -0.38%, compared to ME's ROE of -5.52%. Regarding short-term risk, EXAS is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ME's competition here
EXAS vs INBS Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, INBS has a market cap of 10.9M. Regarding current trading prices, EXAS is priced at $45.66, while INBS trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas INBS's P/E ratio is -0.73. In terms of profitability, EXAS's ROE is -0.38%, compared to INBS's ROE of -2.28%. Regarding short-term risk, EXAS is more volatile compared to INBS. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check INBS's competition here
EXAS vs ADVB Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, ADVB has a market cap of 10.4M. Regarding current trading prices, EXAS is priced at $45.66, while ADVB trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas ADVB's P/E ratio is -3.00. In terms of profitability, EXAS's ROE is -0.38%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, EXAS is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ADVB's competition here
EXAS vs BGLC Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, BGLC has a market cap of 10.1M. Regarding current trading prices, EXAS is priced at $45.66, while BGLC trades at $5.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas BGLC's P/E ratio is -3.44. In terms of profitability, EXAS's ROE is -0.38%, compared to BGLC's ROE of -0.36%. Regarding short-term risk, EXAS is more volatile compared to BGLC. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check BGLC's competition here
EXAS vs CNTG Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, EXAS is priced at $45.66, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas CNTG's P/E ratio is -0.23. In terms of profitability, EXAS's ROE is -0.38%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, EXAS is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check CNTG's competition here
EXAS vs BNR Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, BNR has a market cap of 9M. Regarding current trading prices, EXAS is priced at $45.66, while BNR trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas BNR's P/E ratio is -2.67. In terms of profitability, EXAS's ROE is -0.38%, compared to BNR's ROE of -0.39%. Regarding short-term risk, EXAS is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BNR's competition here
EXAS vs MYNZ Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, MYNZ has a market cap of 7.9M. Regarding current trading prices, EXAS is priced at $45.66, while MYNZ trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas MYNZ's P/E ratio is -0.08. In terms of profitability, EXAS's ROE is -0.38%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, EXAS is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check MYNZ's competition here
EXAS vs BIAF Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, BIAF has a market cap of 7.1M. Regarding current trading prices, EXAS is priced at $45.66, while BIAF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas BIAF's P/E ratio is -0.44. In terms of profitability, EXAS's ROE is -0.38%, compared to BIAF's ROE of -9.30%. Regarding short-term risk, EXAS is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BIAF's competition here
EXAS vs STRR Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, STRR has a market cap of 6.9M. Regarding current trading prices, EXAS is priced at $45.66, while STRR trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas STRR's P/E ratio is -2.77. In terms of profitability, EXAS's ROE is -0.38%, compared to STRR's ROE of -0.04%. Regarding short-term risk, EXAS is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check STRR's competition here
EXAS vs BIAFW Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, BIAFW has a market cap of 5.6M. Regarding current trading prices, EXAS is priced at $45.66, while BIAFW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas BIAFW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.38%, compared to BIAFW's ROE of -9.30%. Regarding short-term risk, EXAS is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check BIAFW's competition here
EXAS vs NVTA Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, EXAS is priced at $45.66, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas NVTA's P/E ratio is -0.00. In terms of profitability, EXAS's ROE is -0.38%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, EXAS is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NVTA's competition here
EXAS vs LMDX Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, EXAS is priced at $45.66, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas LMDX's P/E ratio is -0.01. In terms of profitability, EXAS's ROE is -0.38%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, EXAS is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check LMDX's competition here
EXAS vs LMDXW Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, EXAS is priced at $45.66, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, EXAS's ROE is -0.38%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, EXAS is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check LMDXW's competition here
EXAS vs CHEK Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, CHEK has a market cap of 3.8M. Regarding current trading prices, EXAS is priced at $45.66, while CHEK trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas CHEK's P/E ratio is -0.30. In terms of profitability, EXAS's ROE is -0.38%, compared to CHEK's ROE of -0.37%. Regarding short-term risk, EXAS is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check CHEK's competition here
EXAS vs NDRA Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, NDRA has a market cap of 3.3M. Regarding current trading prices, EXAS is priced at $45.66, while NDRA trades at $4.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas NDRA's P/E ratio is -0.07. In terms of profitability, EXAS's ROE is -0.38%, compared to NDRA's ROE of -2.83%. Regarding short-term risk, EXAS is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check NDRA's competition here
EXAS vs DMTK Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, EXAS is priced at $45.66, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas DMTK's P/E ratio is -0.04. In terms of profitability, EXAS's ROE is -0.38%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, EXAS is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check DMTK's competition here
EXAS vs ISPC Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, ISPC has a market cap of 3.3M. Regarding current trading prices, EXAS is priced at $45.66, while ISPC trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas ISPC's P/E ratio is -0.09. In terms of profitability, EXAS's ROE is -0.38%, compared to ISPC's ROE of -3.95%. Regarding short-term risk, EXAS is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check ISPC's competition here
EXAS vs AWH Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, EXAS is priced at $45.66, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas AWH's P/E ratio is -0.09. In terms of profitability, EXAS's ROE is -0.38%, compared to AWH's ROE of +4.83%. Regarding short-term risk, EXAS is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check AWH's competition here
EXAS vs SQL Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, EXAS is priced at $45.66, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas SQL's P/E ratio is -0.40. In terms of profitability, EXAS's ROE is -0.38%, compared to SQL's ROE of +10.28%. Regarding short-term risk, EXAS is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check SQL's competition here
EXAS vs APDN Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, APDN has a market cap of 1.8M. Regarding current trading prices, EXAS is priced at $45.66, while APDN trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas APDN's P/E ratio is -0.06. In terms of profitability, EXAS's ROE is -0.38%, compared to APDN's ROE of -3.75%. Regarding short-term risk, EXAS is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check APDN's competition here
EXAS vs HTGM Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, EXAS is priced at $45.66, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas HTGM's P/E ratio is -0.03. In terms of profitability, EXAS's ROE is -0.38%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, EXAS is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check HTGM's competition here
EXAS vs BIOC Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, EXAS is priced at $45.66, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas BIOC's P/E ratio is -0.01. In terms of profitability, EXAS's ROE is -0.38%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, EXAS is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check BIOC's competition here
EXAS vs TTOO Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, TTOO has a market cap of 308.5K. Regarding current trading prices, EXAS is priced at $45.66, while TTOO trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas TTOO's P/E ratio is -0.37. In terms of profitability, EXAS's ROE is -0.38%, compared to TTOO's ROE of +1.77%. Regarding short-term risk, EXAS is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check TTOO's competition here
EXAS vs SQLLW Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, SQLLW has a market cap of 116.2K. Regarding current trading prices, EXAS is priced at $45.66, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, EXAS's ROE is -0.38%, compared to SQLLW's ROE of +13.74%. Regarding short-term risk, EXAS is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check SQLLW's competition here
EXAS vs OPGN Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, OPGN has a market cap of 1K. Regarding current trading prices, EXAS is priced at $45.66, while OPGN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas OPGN's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.38%, compared to OPGN's ROE of -1.18%. Regarding short-term risk, EXAS is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check OPGN's competition here
EXAS vs DHR-PA Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, EXAS is priced at $45.66, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, EXAS's ROE is -0.38%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, EXAS is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check DHR-PA's competition here
EXAS vs MEUSW Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, EXAS is priced at $45.66, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas MEUSW's P/E ratio is N/A. In terms of profitability, EXAS's ROE is -0.38%, compared to MEUSW's ROE of -5.52%. Regarding short-term risk, EXAS is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for EXAS.Check MEUSW's competition here
EXAS vs OCDX Comparison August 2025
EXAS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXAS stands at 8.6B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, EXAS is priced at $45.66, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXAS currently has a P/E ratio of -8.38, whereas OCDX's P/E ratio is -42.28. In terms of profitability, EXAS's ROE is -0.38%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, EXAS is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for EXAS.Check OCDX's competition here